Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04060134 · ClinicalTrials.gov registry record
A Retrospective Breast Reconstruction Study
A clinical trial, sponsored by Elutia.
- Completed
- Registry status
- 223
- Enrollment target
NCT04060134: Completed study, sponsored by Elutia.
NCT04060134 is a clinical trial that has completed, run by Elutia. The registered enrollment target is 223 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04060134 has completed, sponsored by Elutia.
- COMPLETED
- Registry status
- 223 participants
- Enrollment target
Study Summary
To collect data on patients who have previously undergone breast reconstruction utilizing SimpliDerm and other HADMs.
Primary Outcome
Occurrence of: infection, hematoma, seroma, capsular contracture, mastectomy skin flap dehiscence, mastectomy skin flap necrosis, expander/implant explantation, red breast syndrome, subsequent surgical interventions related to the breast reconstruction process
Interventions
- OTHER SimpliDerm HADM
- OTHER AlloDerm HADM
- OTHER AlloMax HADM
- OTHER FlexHD HADM
- OTHER DermACELL HADM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2019-11-20 |
| Est. Completion | 2022-06-01 |
What the finished NCT04060134 record still lists
NCT04060134 is an observational study that tracks outcomes without assigning an intervention. The registered 223 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 5 interventions - of which SimpliDerm HADM is the first listed.
NCT04060134 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04060134 about?
NCT04060134 is a clinical study titled "A Retrospective Breast Reconstruction Study". To collect data on patients who have previously undergone breast reconstruction utilizing SimpliDerm and other HADMs.
What is the current status of trial NCT04060134?
This trial is currently completed. The enrollment target is 223 participants. The study started on 2019-11-20. Estimated completion is 2022-06-01.
What interventions are being tested in trial NCT04060134?
The interventions under investigation include: SimpliDerm HADM (OTHER), AlloDerm HADM (OTHER), AlloMax HADM (OTHER), FlexHD HADM (OTHER), DermACELL HADM (OTHER).
Who is sponsoring clinical trial NCT04060134?
This trial is sponsored by Elutia, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06640803 · 223 participants · NA
Sacramento Clinical High Risk for Psychosis Stepped-Care Program
- NCT07175285 · 223 participants
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- NCT07205718 · 223 participants · Phase 1
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI